Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Founded in 1996, Cardinal Partners (CP) is a venture capital firm based in Princeton, New Jersey, with an additional office in San Francisco, California. The firm specializes in early and growth-stage investments in healthcare technology-enabled services and life sciences, participating as the first institutional investor in many portfolio companies. Cardinal Partners has been involved in over 25 IPOs, with a cumulative market valuation exceeding $15 billion for companies funded since 1997.
Cardinal Partners invests in the healthcare sector, particularly in disruptive healthcare technology-enabled services and life sciences, including biopharmaceuticals. The firm engages in institutional financings, selective early-stage rounds, and opportunistic recapitalization. Their investment strategy emphasizes continuous, hands-on collaboration with portfolio companies to maximize growth and success.
Cardinal Partners has backed several notable companies, including: QPID, acquired by eviCore healthcare; Cubist Pharmaceuticals, acquired by Merck & Co. for $8.4 billion; Sapphire-Digital, acquired by Zelis in 2021; Cureatr; Privia Health; Alnylam Pharmaceuticals, which IPO'd in 2004; and Vividion, acquired by Bayer AG for $2 billion.
Email info@cardinalpartners.com with your deck to pitch them.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.